Literature DB >> 9691225

Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig.

R L McLeod1, G Mingo, S O'Reilly, L A Ruck, D C Bolser, J A Hey.   

Abstract

We studied the oral actions of antihistamines from six chemical classes, namely: the ethanolamines (ENA, diphenhydramine and clemastine); ethylenediamines (EDA, pyrilamine and tripelennamine); piperidines (PPD, terfenadine and astemizole); piperazines (PPZ, hydroxyzine and cetirizine); phenothiazines (PTZ, promethazine), and the alkylamines (ALA, chlorpheniramine and bromopheniramine) on cough reflexes, pentobarbital-induced sedation and minute ventilation in the conscious guinea pig. Antihistamines of the ENA class had minimal effects on capsaicin-induced cough although both diphenhydramine (30 and 100 mg/kg p.o.) and clemastine (30 and 100 mg/kg p.o.) increased sedation time (ST). The PPZ class demonstrated both antitussive and sedating activity. The minimum effective oral antitussive dose (MED) of cetirizine and hydroxyzine was 30 and 10 mg/kg, respectively. The EDA did not exhibit antitussive activity. Tripelennamine (10, 30 and 100 mg/kg p.o.) but not pyrilamine enhanced ST. The MED for the PTZ, promethazine, was 10 mg/kg, and at 100 mg/kg promethazine increased ST. The ALA group displayed antitussive activity but only chlorpheniramine (10 mg/kg p. o.) had any effects on ST. The MED for chlorpheniramine and bromopheniramine was 3 and 10 mg/kg p.o., respectively. The PPD antihistamines, namely terfenadine and astemizole, inhibited cough (MED 30 and 10 mg/kg p.o.) without sedative effects. Of the antihistamines tested only promethazine (100 mg/kg p.o.) depressed ventilation responses; however, this dose of promethazine was associated with adverse behavioral effects. The present findings indicate that the antitussive actions of antihistamines are not directly related to histamine H1-receptor blockade because several antihistamines did not antagonize capsaicin-induced cough. In addition, the antitussive actions of antihistamines are independent of their sedative or ventilation effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691225     DOI: 10.1159/000028226

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

Review 1.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

Authors:  Robbie L McLeod; Deen B Tulshian; Donald C Bolser; Geoffrey B Varty; Marco Baptista; Xiomara Fernandez; Leonard E Parra; Jennifer C Zimmer; Christine H Erickson; Ginny D Ho; Yanlin Jia; Fay W Ng; Walter Korfmacher; Xiaoying Xu; John Veals; April Smith-Torhan; Samuel Wainhaus; Ahmad B Fawzi; Theodore M Austin; Margaret van Heek; John A Hey
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

3.  Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function.

Authors:  Peter V Dicpinigaitis; Yvonne E Gayle
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 4.  Current and future centrally acting antitussives.

Authors:  Donald C Bolser
Journal:  Respir Physiol Neurobiol       Date:  2006-03-06       Impact factor: 1.931

Review 5.  Older-generation antihistamines and cough due to upper airway cough syndrome (UACS): efficacy and mechanism.

Authors:  Donald C Bolser
Journal:  Lung       Date:  2007-10-02       Impact factor: 2.584

6.  Management of patients with chronic cough using a clinical protocol: a prospective observational study.

Authors:  Josephine C Ojoo; Caroline F Everett; Siobhain A Mulrennan; Shoaib Faruqi; Jack A Kastelik; Alyn H Morice
Journal:  Cough       Date:  2013-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.